Prostate-Specific Antigen Kinetics After Brachytherapy or External Beam Radiotherapy and Neoadjuvant Hormonal Therapy

Urology

Volumn 69, Issue 1, 2007, Pages 129-133

  Pinkawa, Michael ^a   Fischedick, Karin ^a   Piroth, Marc D ^a   Gagel, Bernd ^a   Borchers, Holger ^a   Jakse, Gerhard ^a   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; IODINE 125; IRIDIUM 192; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; IMPLANT; KINETICS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SALVAGE THERAPY; TREATMENT WITHDRAWAL;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33846545468     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.09.017     Document Type: Article

References (22)

1. Polascik T.J., Oesterling J.E., and Partin A.W. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 162 (1999) 293-306
2. ASTRO Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
3. Horwitz E.M., Thames H.D., Kuban D.A., et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 173 (2005) 797-802
4. D'Amico A.V., Schultz D., Loffredo M., et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 284 (2000) 1280-1283
5. Crook J., Ludgate C., Malone S., et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 15-23
6. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
7. Kucway R., Vicini F., Huang R., et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 167 (2002) 2443-2447
8. Zagars G.K., and Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44 (1997) 213-221
9. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
10. Zietman A.L., Christodouleas J.P., and Shipley W.U. PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure. Int J Radiat Oncol Biol Phys 62 (2005) 714-718
11. Faria S.L., Mahmud S., Souhami L., et al. No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. Urology 67 (2006) 142-146
12. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
13. International Commission on Radiation Units and Measurements. ICRU Report 50: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda, Maryland, International Commission on Radiation Units and Measurements, 1993.
14. Das P., Chen M.H., Valentine K., et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys 54 (2002) 698-702
15. Merrick G.S., Butler W.M., Wallner K.E., et al. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 54 (2002) 450-456
16. Patel C., Elshaikh M.A., Angermeier K., et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 63 (2004) 110-113
17. Hanlon A.L., Pinover W.H., Horwitz E.M., et al. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 50 (2001) 845-849
18. Rosser C.J., Kuban D.A., Levy L.B., et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 168 (2002) 2001-2005
19. Das P., Chen M., Valentine K., et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys 54 (2002) 698-702
20. Padula G.D.A., Zelefsky M.J., Venkatraman E.S., et al. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 439-443
21. Zelefsky M., Yamada J., and Fuks Z. Comparison of 5-year outcomes between conformal LDR brachytherapy and high dose IMRT for patients with localized prostate cancer. Radiother Oncol 71 suppl 2 (2004) S18
22. Sathya J.R., Davis I.R., and Julian J.A. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005) 1192-1199